By Fineline Cube 
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Brukinsa (zanubrutinib) in a new film-coated tablet formulation for all currently approved indications, according to BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235).
Formulation Transition
The transition from capsule to tablet formulation will be implemented globally outside of China in a phased manner starting in 2025. This change is part of BeOne’s commitment to sustainability.
Sustainability Benefits
The new tablet formulation features a 70% reduction in vial size and reduces energy consumption associated with temperature-controlled shipping. This is expected to lower greenhouse gas emissions and global logistics costs, minimizing environmental impact.
US FDA Approval
Earlier in June, the U.S. FDA approved the tablet formulation of zanubrutinib for all five approved indications.-Fineline Info & Tech